Donor ABCB1 3435 C>T genetic polymorphisms influence early renal function in kidney transplant recipients treated with tacrolimus.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Pharmacogenomics (London)

• Publication date

  2016-01-19

• Fields of study

  Medicine

• Identifiers
  DOI 10.2217/pgs.15.165PMID 26784512
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Deceased donor multidrug resistance protein 1 and caveolin 1 gene variants may influence allograft survival in kidney transplantation

  2015cited by this paper
• The donor ABCB1 (MDR-1) C3435T polymorphism is a determinant of the graft glomerular filtration rate among tacrolimus treated kidney transplanted patients

  2015cited by this paper
• Relationship of CYP3A5 genotype and ABCB1 diplotype to tacrolimus disposition in Brazilian kidney transplant patients.

  2014cited by this paper
• Impact of the CYP3A5, CYP3A4, COMT, IL-10 and POR Genetic Polymorphisms on Tacrolimus Metabolism in Chinese Renal Transplant Recipients

  2014cited by this paper
• CYP3A5 and CYP3A4, but not ABCB1 polymorphisms affect tacrolimus dose-adjusted trough concentrations in kidney transplant recipients.

  2014cited by this paper
• Role of pharmacogenomics in dialysis and transplantation

  2014cited by this paper
• Donor ABCB1 genetic polymorphisms influence epithelial-to-mesenchyme transition in tacrolimus-treated kidney recipients.

  2014cited by this paper
• The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients

  2014cited by this paper
• CYP2C8*3 Polymorphism and Donor Age are Associated With Allograft Dysfunction in Kidney Transplant Recipients Treated With Calcineurin Inhibitors

  2013cited by this paper
• Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients.

  2013cited by this paper
• Impact of POR*28 on the Pharmacokinetics of Tacrolimus and Cyclosporine A in Renal Transplant Patients

  2013cited by this paper
• Pharmacogenetics in solid organ transplantation: genes involved in mechanism of action and pharmacokinetics of immunosuppressive drugs.

  2013cited by this paper
• Impact of cytochrome P450 3A and ATP-binding cassette subfamily B member 1 polymorphisms on tacrolimus dose-adjusted trough concentrations among Korean renal transplant recipients.

  2012cited by this paper
• The effect of CYP3A5 6986A>G and ABCB1 3435C>T on tacrolimus dose-adjusted trough levels and acute rejection rates in renal transplant patients: a systematic review and meta-analysis.

  2012cited by this paper
• Donor age and ABCB1 1199G>A genetic polymorphism are independent factors affecting long-term renal function after kidney transplantation.

  2012cited by this paper
• The new CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney transplant patients

  2012cited by this paper
• Donor ABCB1 variant associates with increased risk for kidney allograft failure.

  2012cited by this paper
• The influence of pharmacogenetics and cofactors on clinical outcomes in kidney transplantation

  2011cited by this paper
• Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs

  2011cited by this paper
• CYP3A5 and ABCB1 polymorphisms in donor and recipient: impact on Tacrolimus dose requirements and clinical outcome after renal transplantation.

  2011cited by this paper
• Influence of Cytochrome P450 3A5 (CYP3A5) Genetic Polymorphism on the Pharmacokinetics of the Prolonged-Release, Once-Daily Formulation of Tacrolimus in Stable Renal Transplant Recipients

  2011cited by this paper
• Do Drug Transporter (ABCB1) SNPs Influence Cyclosporine and Tacrolimus Dose Requirements and Renal Allograft Outcome in the Posttransplantation Period?

  2011cited by this paper
• CYP3A5 and ABCB1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation.

  2010cited by this paper
• Optimization of Initial Tacrolimus Dose Using Pharmacogenetic Testing

  2010cited by this paper
• A prospective, open-label, observational clinical cohort study of the association between delayed renal allograft function, tacrolimus exposure, and CYP3A5 genotype in adult recipients.

  2010cited by this paper
• Opportunities to Optimize Tacrolimus Therapy in Solid Organ Transplantation: Report of the European Consensus Conference

  2009cited by this paper
• Donor age and renal P-glycoprotein expression associate with chronic histological damage in renal allografts.

  2009cited by this paper
• A "Silent" Polymorphism in the MDR1 Gene Changes Substrate Specificity

  2007cited by this paper
• Multidrug resistance gene-1 (MDR-1) haplotypes have a minor influence on tacrolimus dose requirements.

  2006cited by this paper
• Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation

  2005cited by this paper
• MDR1 haplotypes derived from exons 21 and 26 do not affect the steady-state pharmacokinetics of tacrolimus in renal transplant patients.

  2004cited by this paper
• Tacrolimus: a further update of its use in the management of organ transplantation.

  2003cited by this paper
• Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients.

  2003cited by this paper
• Human P-glycoprotein transports cyclosporin A and FK506.

  1993cited by this paper
• Supporting Online Material Materials and Methods Som Text Figs. S1 to S8 Table S1 Movies S1 to S3 a " Silent " Polymorphism in the Mdr1 Gene Changes Substrate Specificity Corrected 30 November 2007; See Last Page

  year unknowncited by this paper

• The Effect of Platelet Activity, ABCB1 Genetic Polymorphism, and Renal Function on the Development of Ticagrelor-Related Dyspnea in Patients with Acute Coronary Syndrome

  2024cites this paper
• Gene Polymorphisms Play an Important Role in the Drug Interaction Between Posaconazole and Tacrolimus in Renal Transplant Patients

  2024cites this paper
• Drug–drug interaction between tacrolimus and caspofungin in Chinese kidney transplant patients with different CYP3A5 genotypes

  2024cites this paper
• Donor–Recipient Non-HLA Variants, Mismatches and Renal Allograft Outcomes: Evolving Paradigms

  2022cites this paper
• CYP3A4/5 genotypes and age codetermine tacrolimus concentration and dosage in pediatric heart transplant recipients.

  2022cites this paper
• Drug-induced Fanconi syndrome in patients with kidney allograft transplantation

  2022cites this paper
• Effect of drug combination on tacrolimus target dose in renal transplant patients with different CYP3A5 genotypes

  2022cites this paper
• Case Report: Low Hematocrit Leading to Tacrolimus Toxicity

  2021cites this paper
• Effects and safety evaluation of Wuzhi Capsules combined with tacrolimus for the treatment of kidney transplantation recipients

  2021cites this paper
• Etiological and Clinical Evaluations of Patients with Acute Allograft Dysfunction Within the First Year Address

  2021cites this paper
• Effects of Wuzhi Capsules on Blood Concentration of Tacrolimus in Renal Transplant Recipients

  2019cites this paper
• Effect of tacrolimus dispositional genetics on acute rejection in the first 2 weeks and estimated glomerular filtration rate in the first 3 months following kidney transplantation

  2019cites this paper
• Pharmacogenetics of Membrane Transporters of Tacrolimus in Solid Organ Transplantation

  2018cites this paper
• CYP3A5 and ABCB1 polymorphisms in living donors do not impact clinical outcome after kidney transplantation.

  2018cites this paper
• Risk factors for calcineurin inhibitor nephrotoxicity after renal transplantation: a systematic review and meta-analysis

  2018cites this paper
• Risk factors for calcineurin inhibitor nephrotoxicity after renal transplantation: a systematic review and meta-analysis chronic lesions. 4–6 Surveillance of posttransplantation CNI nephrotoxicity Available diagnostic methods

  2018cites this paper
• Attempted validation of 44 reported SNPs associated with tacrolimus troughs in a cohort of kidney allograft recipients.

  2018cites this paper
• Risk factors for calcineurin inhibitor nephrotoxicity after renal transplantation: a systematic review and meta-analysis

  2018cites this paper
• Genetic predictors of long-term graft function in kidney and pancreas transplant patients.

  2017cites this paper
• The influence of living donor SHROOM3 and ABCB1 genetic variants on renal function after kidney transplantation

  2017cites this paper
• Effects of CYP3A5 and ABCB1 Genetics Variant on Tacrolimus Pharmacokinetics in Algerian adult Kidney Transplant Patients

  2016cites this paper